Skip to main content

Table 1 Characteristics of fasted participants after a 4-week administration of bezafibrate or control

From: Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study

 

Bezafibrate

Control

p

Body mass index (kg/m2)

28.8 ± 1.2

28.6 ± 1.1

0.24

Systolic blood pressure (mmHg)

127 ± 4

125 ± 4

0.34

Diastolic blood pressure (mmHg)

78 ± 3

80 ± 2

0.98

Heart rate (beats/min)

64 ± 2

65 ± 1

0.20

Laboratory data

   

Total-C (mg/dl)

217 ± 9

197 ± 8

0.02

LDL-C (mg/dl)

129 ± 6

135 ± 9

0.57

HDL-C (mg/dl)

46 ± 3

43 ± 3

0.22

TG (mg/dl)

135 ± 24

203 ± 35

<0.01

RLP-C (mg/dl)

5.7 ± 0.7

7.9 ± 1.3

0.02

ApoB-48 (μg/ml)

3.5 ± 0.7

6.0 ± 1.5

0.02

Glucose (mg/dl)

97 ± 3

101 ± 5

0.15

Insulin (μU/ml)

12.7 ± 4.8

8.5 ± 1.4

0.43

HOMA-IR

2.9 ± 0.2

2.1 ± 0.2

0.48

Hemoglobin A1c (%)

5.2 ± 0.3

5.3 ± 0.3

0.17

Pentraxin 3 (ng/ml)

1.5 ± 0.2

1.5 ± 0.2

0.64

Endothelial function

   

Brachial artery diameter (mm)

4.3 ± 0.2

4.3 ± 0.2

0.70

% FMD

6.9 ± 0.7

5.9 ± 0.7

0.04

  1. Data are mean ± SE. Total-C, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TGs, triglycerides; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; HOMA-IR, homeostasis model assessment of insulin resistance; FMD, flow-mediated dilation.